Open in web browser

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

Cystic fibrosis

Top 5 reasons to watch the new cystic fibrosis drug

FDA's approval last week of Vertex Pharmaceutical’s groundbreaking drug lumacaftor/ivacaftor (Orkambi) for cystic fibrosis is certainly good news, but formulary managers need to be aware of the high cost of the drug and other factors. What you need to know

FDA approves Orkambi for treatment of cystic fibrosis

FDA has approved lumacaftor/ivacaftor (Orkambi, Vertex) for the treatment of cystic fibrosis in patients aged 12 years and older.. Study results

CONTINUING EDUCATION

MTM essentials for COPD management: Part 1

This month's CE activity is part of a CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to assist pharmacists in understanding the pathophysiology and pharmacologic treatment of COPD and to discuss how COPD is similar to and different from other chronic respiratory disorders.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT31-KTJ28.

To login to the Online CE Center, go to:
https://web2.uconn.edu/pharmacyce/login.php.
To review your registration page or to register, go to:
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to:
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

5 drug categories having the biggest impact on pharma spending

Cystic fibrosis is one drug category that may command the most impact on pharma spending in the near future. Read about others

July 13, 2015

Related Articles

High healthcare costs driven by spike in Rx costs

Patient access to orphan drugs faces new set of challenges

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click here to contact Editorial. Sales, Reprints, Classified questions? Click here to contact the Sales Team.

ModernMedicine logo
UBM  logo

UBM MEDICA